^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD30-targeted CAR-T immunotherapy

    Related drugs:
    3d
    Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL (clinicaltrials.gov)
    P1/2, N=38, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center | Recruiting --> Active, not recruiting | Trial completion date: Aug 2038 --> Nov 2039 | Trial primary completion date: Sep 2027 --> Dec 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 expression
    |
    TT11
    11d
    Optimization of velocity receptor transduction in CAR T cells. (PubMed, bioRxiv)
    We also observed a log-linear relationship between viral dose and transduction efficiency for a subset of VRs previously tested in various mouse models of human cancer, with VR5αIL8 and VR5αTNFα VRs consistently outperforming VR5αIL5 and V5 (full length native IL5 receptor). Overall, these findings establish an optimized and reproducible framework that offers valuable guidance for the future development and functional study of VR-CAR T cells in cellular therapies for solid tumors.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • IL5 (Interleukin 5)
    13d
    CD30 CAR for CD30+ NSGCT (clinicaltrials.gov)
    P2, N=2, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center | Recruiting --> Active, not recruiting | N=18 --> 2 | Trial completion date: Aug 2030 --> Dec 2030 | Trial primary completion date: Sep 2026 --> Dec 2025
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV • TT11
    22d
    CABAL2: Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas (clinicaltrials.gov)
    P1, N=90, Recruiting, Baylor College of Medicine | Not yet recruiting --> Recruiting
    Enrollment open
    |
    TT11X
    2ms
    CD30 CAR for CD30+ NSGCT (clinicaltrials.gov)
    P2, N=18, Recruiting, UNC Lineberger Comprehensive Cancer Center | Active, not recruiting --> Recruiting | Trial primary completion date: Sep 2025 --> Sep 2026
    Enrollment open • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV • TT11
    4ms
    CD30 CAR for CD30+ NSGCT (clinicaltrials.gov)
    P2, N=18, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center | Recruiting --> Active, not recruiting | Trial completion date: Dec 2026 --> Aug 2030 | Trial primary completion date: Dec 2026 --> Sep 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV • TT11
    4ms
    Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas (clinicaltrials.gov)
    P1, N=18, Recruiting, Baylor College of Medicine | Trial primary completion date: Jun 2025 --> Jun 2026
    Trial primary completion date
    |
    ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    ALK positive • TNFRSF8 positive • ALK negative
    |
    TT11X
    7ms
    Case Report: Bispecific CD20/CD30-targeted chimeric antigen receptor T-cell therapy for non-Hodgkin's lymphoma. (PubMed, Front Immunol)
    The patient received two doses of anti-CD20/CD30-CAR-T therapy administered one month apart...The report underscores the promising therapeutic potential and safety profile of CD20/CD30-directed CAR T-cell therapy. https://www.clinicaltrials.gov, identifier NCT06756321.
    Journal
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    9ms
    CD30 CAR-T in the Treatment of CD30 Positive Relapsed/Refractory Lymphoma (clinicaltrials.gov)
    P=N/A, N=15, Recruiting, Shanxi Bethune Hospital
    New trial
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    11ms
    HSP-CAR30 WITH A HIGH PROPORTION OF LESS-DIFFERENTIATED T CELLS PROMOTES DURABLE RESPONSES IN REFRACTORY CD30+ LYMPHOMA. (PubMed, Blood)
    Our study shows that selection of the epitope targeting CD30 and ex vivo preservation of less-differentiated memory T cells may enhance the efficacy of CART30 in patients with refractory HL. This trial is registered at www.clinicaltrials.gov (NCT04653649).
    Journal
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8) • IL15 (Interleukin 15) • IL21 (Interleukin 21) • IL7 (Interleukin 7)
    11ms
    A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy (clinicaltrials.gov)
    P1, N=9, Recruiting, Affiliated Hospital of Nantong University
    New P1 trial
    |
    EGFR mutation • IDH1 mutation • EGFR amplification • CDKN2A deletion
    |
    cyclophosphamide • fludarabine IV
    1year
    Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=10, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center | Trial completion date: Aug 2039 --> Jul 2037 | Trial primary completion date: Nov 2024 --> Apr 2025
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy • Immunomodulating
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8) • CCR4 (C-C Motif Chemokine Receptor 4)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab)